| Literature DB >> 30026920 |
Carola Severi1, Marilia Carabotti2, Alessia Cicenia1, Lucia Pallotta1, Bruno Annibale2.
Abstract
In the past few decades, the increasing socioeconomic burden of acute diverticulitis (AD) has become evident, and with the growth of the population age, this significant economic impact will likely continue to rise. Furthermore, recent evidence showed an increased rate of hospital admissions especially evident among women and younger individuals. The natural history and pathophysiology of this clinical condition is still to be fully defined, and efforts continue to be made in the identification of risk factors and the establishment of relative preventive strategies. The actual therapeutic strategies aimed to modulate gut microbiota, such as rifaximin or probiotics, or to reduce mucosal inflammation, such as mesalazine, present a relatively poor efficacy for both the prevention of the first AD episode (primary prevention) and its recurrence (secondary prevention). In the last few years, the main goal achieved has been in the management of AD in that uncomplicated AD can, to a larger extent, be managed in an outpatient setting with no or little supportive therapy, a strategy that will certainly impact on the health costs of this disease. The problem of AD recurrence remains a topic of debate. The aim of this review is to present updated evidence on AD epidemiology and relative open clinical questions and to analyze in detail predisposing and protective factors with an attempt to integrate their possible modes of action into the several pathogenic mechanisms that have been suggested to contribute to this multifactorial disease. A unifying hypothesis dealing with the colonic luminal and extra-luminal microenvironments separately is provided. Finally, evidence-based changes in therapeutic management will be summarized. Because of an ascertained multifactorial pathogenesis of uncomplicated and complicated AD, it is probable that a single 'causa prima' will not be identifiable, and a better stratification of patients could allow one to pursue tailored therapeutic algorithm strategies.Entities:
Keywords: Colonic muscle; Diet; Diverticulitis; Drugs; Microbiota; Prevention; Risk factors; Therapy
Year: 2018 PMID: 30026920 PMCID: PMC6039950 DOI: 10.12688/f1000research.14299.1
Source DB: PubMed Journal: F1000Res ISSN: 2046-1402
Summary of predisposing and protective factors associated with primary and secondary prevention of acute diverticulitis.
| Predisposing | Protective | Need to be confirmed | Irrelevant |
|---|---|---|---|
|
|
|
|
|
BMI, body mass index; NSAIDs, non-steroidal anti-inflammatory drugs
Figure 1. Pathogenic unifying hypothesis.
CYT, cytokines; LPS, lipopolysaccharide; ROS, reactive oxygen species.
Acute diverticulitis management and classification according to modified Hinchey and German Society Gastroenterology classifications.
| Modified Hinchey
| German society
| Management |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
| |
|
|
|
*except for immunocompromised patients and severe comorbidities